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Rebuttal to Dr. Stone
Daniel E. Spratt, Michael J. Zelefsky*
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NYDr Stone has raised meritorious points regarding the treat- achieve such high BEDs safely without resorting to exces-
ment of intermediate-risk prostate cancer and the potential
concerns of supplemental external beam radiotherapy
(EBRT) (1). However, within all the arguments he posed to
support the routine use of brachytherapy alone for
intermediate-risk disease, there are inconsistencies. Indeed,
some of his perspectives actually represent cogent reasons
to support our viewpoint for adding supplemental EBRT to
brachytherapy in this patient population. So for this rebuttal,
let’s carefully analyze Dr Stone’s arguments for the use of
brachytherapy alone. The following key points will be criti-
cally assessed: (1) benefit of further dose escalation to allow
the delivery of a higher biologic effective dose (BED); (2) the
efficacy for achieving the ‘‘trifecta’’ with brachytherapy
alone, namely, low urinary toxicity and maintained sexual
function with durable tumor control; (3) secondary malig-
nancy risk with EBRT; and (4) theoretical financial burden
of more aggressive therapy using supplemental EBRT.
Perhaps, unwittingly, Dr Stone is actually arguing in
favor of supplemental EBRT by reinforcing the notion that
further dose escalation improves tumor outcomes, and we
could not agree more. As shown in our table 1 (2), when
comparing series with $8-year outcomes, most implant
alone reports have noted biochemical failure ratesO20%,
whereas combination therapy series have reported failure
of approximately 10%. This is consistent with the data Dr
Stone presented from Mount Sinai that reported that BED
O200 Gy resulted in improved biochemical control
compared with lower doses (3). Dr Stone had also reported
that dosesO220 Gy were associated with further improve-
ments in biochemical control (4). To achieve these kind of
dose levels with an implant alone, one would require an
I-125 D90 coverage of approximately 210 Gy . now that
is a hot implant (hotter than any of the D90s even in his
tables)! The addition of supplemental EBRT can readily* Corresponding author. Department of Radiation Oncology, Memorial
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sary dose coverage for extraprostatic disease.
A logical concern that Dr Stone brings forth is that
the better tumor control with high BEDs may negate the
ability to achieve the coveted ‘‘trifecta’’ of brachytherapy
and result in greater risks for long-term toxicity. However,
the concern for toxicity with such high BEDs with combina-
tion therapy has been evaluated in three multi-institutional
prospective Phase II trials that did not even use intensity-
modulated radiotherapy (IMRT) (let alone image-guided
radiotherapy [IGRT]) and had wide O1.5-cm margins on
the prostate for the EBRT component. The CALGB reported
0.0% acute gastrointestinal (GI) Grade$3 toxicity and 0.0%
late GI Grade $3 (5)! The Radiation Therapy Oncology
Group (RTOG) reported only 2.9% late Grade $3 GI
toxicity Reference 10 (Lawton et al) Dr Stone cited multiple
retrospective single institution studies depicting the concern
for increased toxicity with supplemental EBRT (6, 7). Why
use data with inherent biases from disparate study methodol-
ogies when it is clear from prospective multi-institutional
trials that the excessive toxicity risk is exaggerated?
The theoretical risks Dr Stone touched on regarding
secondary malignancies should be kept in the context of
absolute risk. Data from one of the largest studies performed
on over 122,000 men comparing RT to prostatectomy found
that the radiation-associated second malignancy rates were 1
in 290 (8). Remember, this 0.3% absolute risk is radiotherapy
(RT) compared with no RT. Dr Stone cited data demon-
strating a relative 18% increased risk in second cancers from
implant to combination therapy (4.7% to 5.7%); however,
this would correlate to an absolute increased risk of only
0.05% when adding supplemental EBRTover implant alone!
Lastly, Dr Stone is correct that the upfront costs of
supplemental EBRT are more expensive than implant
alone. However, the Markov model he cited reported by
Cooperberg et al. was driven by the immense increased
toxicity with combination therapy and assumed a fourfold
higher risk of acute GI toxicity and nearly twofold
increase in GI late toxicity with the additional ofhed by Elsevier Inc. All rights reserved.
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the RTOG and CALGB for combination therapy cited
previously, these estimates are exaggerated (5, 10).
Assuming a minimal increase in toxicity, and a conserva-
tive estimate of approximately 10% improvement in
biochemical control with the addition of supplemental
EBRT (Cooperberg estimated 12%), the costs of salvage
therapy will dominate the overall costs of therapy. The
estimated annual cost of a biochemical recurrence treated
with ADT is $2566, one-time cost of salvage RT is
$27,586, and salvage prostatectomy is $8547. With
success rates of salvage therapy often less than 50%,
coupled with the costs of increased chronic toxicity from
salvage therapies, the benefit of supplemental EBRT likely
outweighs any initial upfront cost saving of implant alone
for patients with intermediate-risk disease.
In summary, dose escalation has a proven benefit for
intermediate-risk prostate cancer. Further dose escalation
appears to further enhance biochemical and local control,
and this can readily be achieved with supplemental EBRT
while providing the needed extraprostatic coverage for this
cohort of patients. Supplemental EBRT is safe with very
low rates of severe late toxicity, clinically minute increased
risk of secondary radiation included malignancies, and
likely comparable costs to implant alone. We agree that
low volume intermediate-risk disease can be adequately
treated with implant alone, yet for many patients with
moderate or large volume disease, we believe that the addi-
tion of supplemental EBRT is paramount in achieving
durable long-term tumor control and the most efficacious
radiotherapeutic treatment intervention for these patients.References
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